Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

Multicentric Randomized Phase 2. Immunotherapy With CpG-ODN in Malignant Glioblastoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00190424

Enrollment

Registered

2005-09-19

Start date

2005-09-30

Completion date

2010-10-31

Last updated

2012-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Keywords

Glioblastoma, Immunotherapy

Brief summary

The purpose of this study is to determine whether the immunostimulating agent CpG-ODN is effective in the treatment of glioblastoma

Interventions

DRUGCpG-ODN

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Glioblastoma * Karnofsky Performance Status ≥ 60%

Exclusion criteria

* Severe or uncontrolled systemic disease * Active auto-immune disease * Uncontrolled epilepsia * Platelets \< 100 000/mm3 ; or Neutrophils \<500 /mm3 ; or lymphocytes \<300/ mm3

Design outcomes

Primary

Measure	Time frame
Survival	2 years

Secondary

Measure	Time frame
Progression-free survival	2 years
Tolerance	2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026